5 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 5 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Endo International Plc (ENDP) earns a D this week, moving down from last week’s grade of C. Endo International Plc provides specialty healthcare solutions in the United States and internationally. The company also gets F’s in earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ENDP stock.

Slipping from a C to a D rating, Astrazeneca PLC Sponsored ADR (AZN) takes a hit this week. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Imprimis Pharmaceuticals, Inc. (IMMY) experiences a ratings drop this week, going from last week’s C to a D. Imprimis Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of non-invasive topically delivered medications. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMMY stock.

Repros Therapeutics Inc. (RPRX) is having a tough week. The company’s rating falls from a D to a F. Repros Therapeutics Inc. is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RPRX stock.

Bio-Path Holdings, Inc. (BPTH) declines this week from a D to a F. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of BPTH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/11/5-pharmaceuticals-stocks-to-sell-now/.

©2021 InvestorPlace Media, LLC